Online medical consultation for Wegovy.

Semaglutide is a synthetic peptide that mimics GLP-1 (glucagon-like peptide-1), a hormone the gut releases after a meal. It is the same molecule sold under Ozempic (type-2 diabetes) and Wegovy (weight management) — the active ingredient is identical; the dosing and approved indication differ.

Its effect on weight comes from three combined actions: it increases the feeling of fullness after eating, slows gastric emptying, and modulates the insulin/glucagon response to glucose.

Semaglutide binds to GLP-1 receptors in the pancreas, the digestive tract and brain areas that regulate appetite (hypothalamus and brainstem). That binding produces three clinically measurable effects:

• Satiety: patients describe getting full earlier and staying full longer, which reduces intake without the need for calorie counting.
• Slowed gastric emptying: food stays in the stomach longer, which also explains the mild nausea reported in the first month.
• Glycaemic regulation: it increases insulin secretion under hyperglycaemia and suppresses glucagon, improving blood-sugar control.

The effect on weight unfolds gradually over months; phase-III clinical trials report an average sustained loss of 10–15 % of starting weight when combined with diet and physical-activity changes.

The EMA indication in weight management is for adults with BMI ≥ 30 kg/m² (obesity), or ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity (hypertension, type-2 diabetes, dyslipidaemia, sleep apnoea).

The licensed doctor reviews your questionnaire to verify the indication, rule out contraindications (personal or family history of medullary thyroid carcinoma, MEN-2, prior pancreatitis, pregnancy, breastfeeding) and check for interactions with your current medication before prescribing.

If your case is not eligible, the doctor tells you through the private chat in your account and the €25 is refunded in full.

Treatment starts at a low dose and escalates gradually over 16 weeks to minimise gastrointestinal effects. That titration is standard for every GLP-1 analogue, and the doctor decides the schedule based on your response and tolerance.

Visible changes in weight usually appear between weeks 8 and 12, with the largest cumulative loss between months 6 and 12. The medication continues as long as the doctor judges the benefit/risk balance favourable and under ongoing clinical follow-up.

Follow-up happens exclusively through the private chat in your Hi-Doctor account — no WhatsApp, no SMS, no third-party apps. You can reach the doctor whenever you have questions or side effects.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation. They tend to appear in the first weeks and improve with dose adjustment. Most are mild and temporary, but the doctor adjusts the schedule if they interfere with your routine.

It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, MEN-2, active pancreatitis, severe renal impairment, during pregnancy and breastfeeding. The doctor reviews the full questionnaire before prescribing.

After issuing the REMPE prescription, the doctor recommends periodic follow-up to review tolerance, weight, blood pressure and, if appropriate, blood glucose. Every follow-up is logged in your account chat.